Delivery strategies of amphotericin B for invasive fungal infections

Acta Pharm Sin B. 2021 Aug;11(8):2585-2604. doi: 10.1016/j.apsb.2021.04.010. Epub 2021 Apr 29.


Invasive fungal infections (IFIs) represent a growing public concern for clinicians to manage in many medical settings, with substantial associated morbidities and mortalities. Among many current therapeutic options for the treatment of IFIs, amphotericin B (AmB) is the most frequently used drug. AmB is considered as a first-line drug in the clinic that has strong antifungal activity and less resistance. In this review, we summarized the most promising research efforts on nanocarriers for AmB delivery and highlighted their efficacy and safety for treating IFIs. We have also discussed the mechanism of actions of AmB, rationale for treating IFIs, and recent advances in formulating AmB for clinical use. Finally, this review discusses some practical considerations and provides recommendations for future studies in applying AmB for combating IFIs.

PMID:34522599 | PMC:PMC8424280 | DOI:10.1016/j.apsb.2021.04.010

Source: Industry